Navigation Links
Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
Date:12/11/2012

ATLANTA, Dec. 11, 2012 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced follow-up findings from an ongoing, open-label, Phase 2, single-agent study suggesting that in patients with relapsed or refractory mantle cell lymphoma (MCL), both those who were bortezomib-naive and bortezomib-exposed, the investigational oral agent ibrutinib (PCI-32765) resulted in high and durable responses and was generally well tolerated. In the study, 111 patients received ibrutinib and 110 were evaluable for efficacy. The median follow-up time was 9.2 months, with a range of time to response to treatment of 1.4 to 16.4 months.

The results were presented by lead investigator Michael L. Wang, M.D., associate professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, at the 54th Annual Meeting of the American Society of Hematology (ASH) in Atlanta, Ga. The study showed an overall response rate (ORR) of 68 percent, including a complete response (CR) of 22 percent and a partial response (PR) of 46 percent with a median progression free survival (PFS) estimated at 13.9 months. Results were similar between the bortezomib-naive and bortezomib-exposed patients.

Long-term follow up of the initial 51 patients enrolled in this study that were presented last year at ASH shows there was an incremental improvement in the response rate over time. The ORR increased for this patient subset from 69 percent in 2011 to an ORR of 75 percent in 2012, with the CR increasing from 16 percent to 39 percent over the same period.

"Now with a larger number of patients studied, we see the overall response rate remains durable and the safety profile continues to appear manageable," said Dr. Wang. "In addition, what is particularly encouraging is that with longer follow-up there is an incremental increase in the number of patients who achiev
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Six-Year Follow-Up Data for SPRYCEL®? (dasatinib) 100 mg Once Daily Demonstrates 71 Percent Overall Survival in Patients with Chronic-Phase Chronic Myeloid Leukaemia Resistant or Intolerant to Imatinib
2. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
3. VeriStrat® Test Results Correlate with Survival Outcomes in Advanced Lung Cancer
4. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
5. Alexza to Announce 2012 First Quarter Financial Results on Thursday, May 10, 2012
6. 3SBio Inc. Schedules Unaudited First Quarter 2012 Results
7. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
8. Perrigo Company Will Release Third Quarter Fiscal 2012 Results On May 8, 2012
9. Genomic Health to Announce First Quarter 2012 Financial Results and Host Conference Call on Wednesday, May 2, 2012
10. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
11. STAAR Surgical Announces First Quarter 2012 Results Release Date and Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014 Research and Markets  has announced ... 2014-2018" report to their offering. ... is a hollow needle commonly used with a syringe ... extract fluids from it. A hypodermic needle is used ... that cannot be ingested. Hypodermic needles are broadly classified ...
(Date:7/11/2014)... -- On Thursday, July 10, 2014, ... Jones Industrial Average finished the day 0.42% lower at 16,915.07, ... losses were broad based as eight out of ten sectors ... Sector Index ended the day at 711.88, down 0.02%, while ... Investor-Edge has initiated coverage on the following equities: Covidien PLC ...
(Date:7/11/2014)... , July 11, 2014  Veran Medical ... announced today the positive, cost-effective final results ... SPiNPerc™ procedure. The SPiNPerc endobronchial percutaneous biopsy ... percutaneous approach to biopsy when a traditional ... and physicians experience positive financial outcomes when ...
Breaking Medicine Technology:Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4Veran Medical Publishes Lung Cancer Patient Management Study 2
... OAK BROOK, Ill. , July 12 The University ... agreement to Ascent, a leader in health care resource sustainability. The agreement, ... 1, 2010 . Under the contract, Ascent will offer single-use device (SUD) ... , , , ...
... July 12 ( http://www.myprgenie.com ) -- Medrium, Inc., one ... announced it has signed a partnership agreement with RelayHealth to use ... LabCorp and to provide LabCorp results to physicians utilizing the Medrium ... , ...
Cached Medicine Technology:University HealthSystem Consortium Awards Single-Source Agreement to Ascent for Medical Device Reprocessing Services 2University HealthSystem Consortium Awards Single-Source Agreement to Ascent for Medical Device Reprocessing Services 3Medrium Partners With RelayHealth 2Medrium Partners With RelayHealth 3
(Date:7/13/2014)... Recently, iFitDress.com, one of the most famous ... collection of brown evening dresses for worldwide ... at discounted prices, up to 50% off. , ... they are carefully made according to most fashionable styles. ... also offers pretty accessories: wedding shoes, dancing shoes, sandals, ...
(Date:7/13/2014)... variations in the quality of care are the most ... varies widely between regions within Europe, according to the ... date, published in The Lancet Oncology . , ... cancers of the blood has increased over the past ... targeted drugs in the early 2000s such as rituximab ...
(Date:7/13/2014)... research in Nature Genetics identifies a ... that causes eosinophillic esophagitis (EoE), opening up potential ... food allergy. , EoE is a chronic ... triggered by allergic hypersensitivity to certain foods and ... cells called eosinophils (part of the body,s immune ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 Victorian Hotel ... by promoting the rental of bikes for its "Cycle ... downtown Victorian Hotel to tour the area using a ... tax. Bicycle enthusiasts love to call Vancouver home, as ... for cycle travel and picturesque journeys through the countryside. ...
(Date:7/13/2014)... 2014 Advanced boilers are preferred ... amount of fossil fuels, produce high-capacity power, emit ... increased global warming and climate change concerns, many ... harmful gas emissions and pollutants coming from fossilfuel-based ... the global advance boilers market., The global power ...
Breaking Medicine News(10 mins):Health News:2014 Brown Evening Dresses Added To iFitDress.com 2Health News:The Lancet Oncology: Differences in treatment likely to be behind differing survival rates for blood cancers between regions within Europe 2Health News:The Lancet Oncology: Differences in treatment likely to be behind differing survival rates for blood cancers between regions within Europe 3Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 2Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 3Health News:Victorian Hotel Creates Excitement by Adding "Cycle the City" Bike Rentals for Its Vancouver Hotel Rooms 2Health News:North America Advanced Boilers Market is Expected to Reach $518.7billion by 2019 - New Report by MicroMarket Monitor 2Health News:North America Advanced Boilers Market is Expected to Reach $518.7billion by 2019 - New Report by MicroMarket Monitor 3
... Brain Center America,s New Neuroactive Exercise Bike Trains the Body and Brain ... ... Fitness centers are entering the next lap of their evolution with the ... body and the brain as a joint fitness program , Stephane Bergeron, ...
... Holdings Inc.,(OTC Bulletin Board: CLXS), a leading developer ... that their life science research,portal http://www.BiomedExperts.com ... in December has exploded to over 60,000 per ... , (Logo: ...
... Inc., the nation,s largest independent behavioral health care ... an agreement with CareIntegra to provide enhanced integrated ... product offerings. (Logo: http://www.newscom.com/cgi-bin/prnh/20090106/PH55551LOGO ... ValueOptions(R) will collaborate to develop and conduct a ...
... TV Teacher, LLC(TM) announces the,donation of their video-modeling programs ... Bronx, and Staten Island. , ... Ellis, a mother struggling to help her frustrated five-year-old ... an unsuccessful two years of,"traditional" therapy, she realized she ...
... Pharmaceutical,Inc. (Nasdaq: BMRN ) today announced that ... company update at the 27th,Annual J.P. Morgan Healthcare Conference ... a.m. PT. , Interested parties ... call,via the investor section of the BioMarin website, ...
... Jan. 7 Atlanta-based Billian Publishing, Inc.,owners of ... , (Logo: ... Porter Research was founded in 1989 just as ... of accelerated innovation. Since then, new,and established companies ...
Cached Medicine News:Health News:Neuroactive Bike: America's First And Only Mind-Body Fitness Equipment Used For The Ultimate Brain Fitness Gym Program Launched This Month At Lady Of America Fitness Center 2Health News:Neuroactive Bike: America's First And Only Mind-Body Fitness Equipment Used For The Ultimate Brain Fitness Gym Program Launched This Month At Lady Of America Fitness Center 3Health News:Neuroactive Bike: America's First And Only Mind-Body Fitness Equipment Used For The Ultimate Brain Fitness Gym Program Launched This Month At Lady Of America Fitness Center 4Health News:Collexis BiomedExperts Hits 80,000 Registered Users Within the First Year! 2Health News:Collexis BiomedExperts Hits 80,000 Registered Users Within the First Year! 3Health News:ValueOptions(R) Enters Agreement with CareIntegra to Provide Integrated Health Services 2Health News:New York Schools Receive Program for Children with Autism 2Health News:BioMarin to Present at the 27th Annual J.P. Morgan Healthcare Conference 2Health News:Billian Publishing, Inc. Announces Acquisition of Porter Research 2
CRP Liquid Conrtols level 3...
Therapeutic Drug Calibrator Series...
The IRN method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of iron in serum....
The AST method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of aspartate aminotransferase activity in serum or plasma...
Medicine Products: